Denmark-based Novo Nordisk wasn’t prepared for Wegovy and Ozempic — which are approved for weight-loss and diabetes, respectively — to go viral, The Wall Street Journal reported Dec. 4.
Read the full post on Becker's Hospital Review - Healthcare News
